A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects

Toxicology in Vitro

Volumn 27, Issue 5, 2013, Pages 1589-1595

  Kustermann, S ^a   Boess, F ^a   Buness, A ^a,c   Schmitz, M ^b   Watzele, M ^b   Weiser, T ^a   Singer, T ^a   Suter, L ^a   Roth, A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cell cycle; Cytotoxicity assay; In vitro; Neutral red uptake assay; XCELLigence

Indexed keywords

CYCLOSPORIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DASATINIB; ETOPOSIDE; GEFITINIB; IMATINIB; INDOMETACIN; LAPATINIB; LINDANE; METHOTREXATE; NEUTRAL RED; SORAFENIB; SUNITINIB; VANDETANIB;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG DETERMINATION; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; IMPEDANCE; IMPEDANCE BASED REAL TIME ASSAY; IN VITRO STUDY; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; TOXICITY TESTING;

ANIMALS; BIOLOGICAL ASSAY; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTATIC AGENTS; CYTOTOXINS; ELECTRIC IMPEDANCE; MICE; NEUTRAL RED; NIH 3T3 CELLS;

EID: 84877662963     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.08.019     Document Type: Article

References (31)

1. Abassi Y.A., Xi B., Zhang W., Ye P., Kirstein S.L., Gaylord M.R., Feinstein S.C., Wang X., Xu X. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem. Biol. 2009, 16:712-723.
2. Asphahani F., Zhang M. Cellular impedance biosensors for drug screening and toxin detection. Analyst 2007, 132:835-841.
3. Atienza J.M., Yu N., Kirstein S.L., Xi B., Wang X., Xu X., Abassi Y.A. Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev. Technol. 2006, 4:597-607.
4. Bergamo A., Gagliardi R., Scarcia V., Furlani A., Alessio E., Mestroni G., Sava G. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J. Pharmacol. Exp. Ther. 1999, 289:559-564.
5. Borenfreund E., Puerner J.A. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 1985, 24:119-124.
6. Denelavas A., Weibel F., Prummer M., Imbach A., Clerc R.G., Apfel C.M., Hertel C. Real-time cellular impedance measurements detect Ca(2+) channel-dependent oscillations of morphology in human H295R adrenoma cells. Biochim. Biophys. Acta 2011, 1813:754-762.
7. Giaever I., Keese C.R. Use of electric fields to monitor the dynamical aspect of cell behavior in tissue culture. IEEE Trans. Biomed. Eng. 1986, 33:242-247.
8. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
9. Hoffman R.M. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J. Clin. Lab. Anal. 1991, 5:133-143.
10. Houck K.A., Kavlock R.J. Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol. Appl. Pharmacol. 2008, 227:163-178.
11. Huang X., Greve D.W., Nguyen D.D., Domach M.M. Impedance based biosensor array for monitoring mammalian cell behavior. Proc. IEEE Sensors 2003, 1-2:304-309.
12. Irelan J.T., Wu M.J., Morgan J., Ke N., Xi B., Wang X., Xu X., Abassi Y.A. Rapid and quantitative assessment of cell quality, identity, and functionality for cell-based assays using real-time cellular analysis. J. Biomol. Screening 2011, 16:313-322.
13. Ke N., Wang X., Xu X., Abassi Y.A. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol. Biol. 2011, 740:33-43.
14. Ke N., Xi B., Ye P., Xu W., Zheng M., Mao L., Wu M.J., Zhu J., Wu J., Zhang W., Zhang J., Irelan J., Wang X., Xu X., Abassi Y.A. Screening and identification of small molecule compounds perturbing mitosis using time-dependent cellular response profiles. Anal. Chem. 2010, 82:6495-6503.
15. Kepp O., Galluzzi L., Lipinski M., Yuan J., Kroemer G. Cell death assays for drug discovery. Nat. Rev. Drug Discovery 2011, 10:221-237.
16. Melino G. Discovery of the ubiquitin proteasome system and its involvement in apoptosis. Cell Death Differ. 2005, 12:1155-1157.
17. Morabito A., Piccirillo M.C., Falasconi F., De Feo G., Del Giudice A., Bryce J., Di Maio M., De Maio E., Normanno N., Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14:378-390.
18. Nam S., Williams A., Vultur A., List A., Bhalla K., Smith D., Lee F.Y., Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 2007, 6:1400-1405.
19. O'Brien P., Haskins J.R. In vitro cytotoxicity assessment. Methods Mol. Biol. 2007, 356:415-425.
20. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
21. Olaharski A.J., Uppal H., Cooper M., Platz S., Zabka T.S., Kolaja K.L. In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicol. Lett. 2009, 188:98-103.
22. Ozsvari B., Puskas L.G., Nagy L.I., Kanizsai I., Gyuris M., Madacsi R., Feher L.Z., Gero D., Szabo C. A cell-microelectronic sensing technique for the screening of cytoprotective compounds. Int. J. Mol. Med. 2010, 25:525-530.
23. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 2003, 75:355-367.
24. Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 2008, 3:1125-1131.
25. Rich I.N. In vitro hematotoxicity testing in drug development: a review of past, present and future applications. Curr. Opin. Drug Discovery Dev. 2003, 6:100-109.
26. Russell W.M. The development of the three Rs concept. Altern. Lab. Anim. 1995, 23:298-304.
27. Shawver L.K., Slamon D., Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
28. Sundman-Engberg B., Tidefelt U., Paul C. Toxicity of cytostatic drugs to normal bone marrow cells in vitro. Cancer Chemother. Pharmacol. 1998, 42:17-23.
29. Valeriote F., van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975, 35:2619-2630.
30. Xi B., Yu N., Wang X., Xu X., Abassi Y.A. The application of cell-based label-free technology in drug discovery. Biotechnol. J. 2008, 3:484-495.
31. Xia M., Huang R., Witt K.L., Southall N., Fostel J., Cho M.H., Jadhav A., Smith C.S., Inglese J., Portier C.J., Tice R.R., Austin C.P. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perspect. 2008, 116:284-291.